Valneva vaccinates first participant in pediatric trial of single-shot chikungunya vaccine

Saint-herblain (france), january 10, 2024 – valneva se (nasdaq: valn; euronext paris: vla) today announced that the first participant has been vaccinated in the phase 2 clinical trial evaluating the safety and immunogenicity in children of two different dose levels of valneva's single-shot chikungunya vaccine. the company reported positive pivotal phase 3 data in adolescents two months ago confirming the immunogenicity and safety profile observed in adults1.there is currently no approved chikungunya vaccine for children and valneva's vaccine ixchiq® is currently the only licensed chikungunya vaccine2 to address this unmet medical need in adults aged 18 years and older who are at increased risk of exposure to the virus. once available, the phase 2 pediatric data are intended to support a phase 3 pivotal study in children with the objective to extend the label in this age group following initial regulatory approvals in adults and possibly in adolescents.
VALN Ratings Summary
VALN Quant Ranking